File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications

TitleOcular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications
Authors
Issue Date2014
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
Diabetes Care, 2014, v. 37 n. 4, p. 900-5 How to Cite?
AbstractOcular anti-vascular endothelial growth factor (VEGF) therapy represents one of the most significant advances in modern medicine. The introduction and widespread use of ocular anti-VEGF therapy for age-related macular degeneration heralded a new era in the treatment of vascular and exudative diseases of the retina. Its expanding indications now include diabetic macular edema and proliferative diabetic retinopathy, two vision-threatening forms of diabetic retinopathy. It is widely anticipated that ocular anti-VEGF therapy could spark a dramatic shift in the treatment paradigm for diabetic retinopathy. However, despite its clear efficacy shown in clinical trials, the dynamic landscape of evolving medical, ethical, and economic issues related to this new treatment suggests significant challenges ahead. In this article, we provide a discussion of this topic as part of this two-part Bench to Clinic narrative. Here, our Clinic contribution provides an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy, and highlights the hopes and fears of this new treatment from clinical and public health standpoints. In the Bench narrative that precedes this contribution, Simo et al. provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy.
Persistent Identifierhttp://hdl.handle.net/10722/202109
ISSN
2015 Impact Factor: 8.934
2015 SCImago Journal Rankings: 5.827
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, NDen_US
dc.contributor.authorWong, YHIen_US
dc.contributor.authorWong, TYen_US
dc.date.accessioned2014-08-21T08:04:23Z-
dc.date.available2014-08-21T08:04:23Z-
dc.date.issued2014en_US
dc.identifier.citationDiabetes Care, 2014, v. 37 n. 4, p. 900-5en_US
dc.identifier.issn0149-5992en_US
dc.identifier.urihttp://hdl.handle.net/10722/202109-
dc.description.abstractOcular anti-vascular endothelial growth factor (VEGF) therapy represents one of the most significant advances in modern medicine. The introduction and widespread use of ocular anti-VEGF therapy for age-related macular degeneration heralded a new era in the treatment of vascular and exudative diseases of the retina. Its expanding indications now include diabetic macular edema and proliferative diabetic retinopathy, two vision-threatening forms of diabetic retinopathy. It is widely anticipated that ocular anti-VEGF therapy could spark a dramatic shift in the treatment paradigm for diabetic retinopathy. However, despite its clear efficacy shown in clinical trials, the dynamic landscape of evolving medical, ethical, and economic issues related to this new treatment suggests significant challenges ahead. In this article, we provide a discussion of this topic as part of this two-part Bench to Clinic narrative. Here, our Clinic contribution provides an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy, and highlights the hopes and fears of this new treatment from clinical and public health standpoints. In the Bench narrative that precedes this contribution, Simo et al. provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy.en_US
dc.languageengen_US
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/en_US
dc.relation.ispartofDiabetes Careen_US
dc.titleOcular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applicationsen_US
dc.typeArticleen_US
dc.identifier.emailCheung, ND: dc555@hku.hken_US
dc.identifier.emailWong, YHI: wongyhi@hku.hken_US
dc.identifier.authorityCheung, ND=rp01752en_US
dc.identifier.authorityWong, YHI=rp01467en_US
dc.identifier.doi10.2337/dc13-1990en_US
dc.identifier.pmid24652721-
dc.identifier.hkuros233179en_US
dc.identifier.volume37en_US
dc.identifier.issue4en_US
dc.identifier.spage900en_US
dc.identifier.epage5en_US
dc.identifier.isiWOS:000333414700016-
dc.publisher.placeUnited Statesen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats